Experimental lung cancer drug offered through compassionate access program
NCT ID NCT04830202
Summary
This program provides eligible patients with non-small cell lung cancer access to an investigational drug called telisotuzumab vedotin before it receives full regulatory approval. It is designed for patients who have no other suitable treatment options and do not qualify for ongoing clinical trials. A doctor must determine if the potential benefits outweigh the risks for each individual patient.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.